Adam B. Weiner, Faculty at Cedars-Sinai Medical Center, shared an article by Giulia Marvaso, et al. on X:
“SBRT + ADT for oligometastatic prostate cancer.
RADIOSA trial – The Lancet Oncology.
Six months of ADT prolonged time to clinical progression from 15 to 32 months.”
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.
Authors: Giulia Marvaso, et al.
Charles Jiang, Assistant Professor of Internal Medicine at UT Southwestern Medical Center, reshared the post on X, adding:
“Excellent result!
Personally would love to see more data using short term Arpi (with and without ADT) in psma pet area.”